26626-12-0

Basic information

• Product Name: β-Hydromorphol
• Synonyms: (5R,6R)-17-Methyl-4,5-epoxymorphinan-3,6β-diol;6β-Hydromorphol;Dihydro-α-isomorphine;β-Hydromorphol;(5α,6β)-4,5-Epoxy-17-Methyl-Morphinan-3,6-diol;IJVCSMSMFSCRME-ZBVQWWBFSA-N
• CAS NO: 26626-12-0
• Molecular Formula: C₁₇H₂₁NO₃
• Molecular Weight: 287.35354
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 26626-12-0.mol
• Article Data: 13

Chemical Properties

• Melting Point: 225 °C
• Boiling Point: 475.4°Cat760mmHg
• Flash Point: 241.3°C
• Appearance: /
• Density: 1.4g/cm³
• Vapor Pressure: 7.65E-10mmHg at 25°C
• Refractive Index: 1.69
• PKA: 9.56±0.40(Predicted)
• CAS DataBase Reference: β-Hydromorphol(CAS DataBase Reference)
• NIST Chemistry Reference: β-Hydromorphol(26626-12-0)
• EPA Substance Registry System: β-Hydromorphol(26626-12-0)

Safety Data

• Hazardous Substances Data: 26626-12-0(Hazardous Substances Data)

Usage

Description

6β-Hydromorphol, also known as Hydromorphone metabolite, is an analytical reference material that is structurally similar to known opioids. It is a metabolite of hydromorphone, a semi-synthetic opioid analgesic used for the management of moderate to severe pain.
Used in Pharmaceutical Industry:
6β-Hydromorphol is used as a research and forensic tool for the development and testing of new pharmaceutical compounds and for the identification and analysis of opioids in biological samples.
Used in Forensic Science:
6β-Hydromorphol is used as an analytical reference material for forensic applications, such as drug testing and toxicology, to help identify and quantify the presence of opioids in biological samples, including blood, urine, and tissue.
Used in Pain Management Research:
6β-Hydromorphol is used as a research compound to study the metabolism and pharmacokinetics of hydromorphone, which can help in understanding the drug's efficacy, safety, and potential side effects in pain management.

InChI:InChI=1/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11-,13+,16+,17-/m0/s1

Upstream product

• 143-70-4 morphine 
• 71-68-1 hydromorphone hydrochloride 
• 58752-60-6 3-O-acetyldihydromorphine 
• 52-26-6 morphine hydrochloride 
• 57-27-2 MORPHIN 
• 125-29-1 Hydrocodone 
• 23095-84-3 [3H]-Morphine 3-sulfate 
• 503441-35-8 neopine methyl ether 
• 125-28-0 dihydrocodeine 
• 33049-61-5 (-)-tetrahydrothebaine 
• 76-57-3 codeine 
• 107-15-3 ethylenediamine 
• 466-99-9 hydromorphone 
• 509-71-7 Dihydroheroin 

Downstream Products

• 466-99-9 hydromorphone 
• 509-60-4 dihydromorphine 
• 57366-19-5 4,5α-epoxy-17-methyl-3-(1-phenyl-1H-tetrazol-5-yloxy)-morphinan-6α-ol 
• 22222-98-6 3-acetoxy-6-β-acetylthiodihydromorphine 
• 58752-60-6 3-O-acetyldihydromorphine 
• 302965-12-4 4,5-epoxy-17-methyl-(5α,6α)-morphinan-3,6-diol 3-benzoate 
• 70001-26-2 Dihydromorphine 6-β-D-glucuronide 
• 302965-08-8 C₄₃H₅₃NO₁₃ 
• 130178-43-7 6-β-<5-nitro-2-pyridinesulfenyl>thio-dihydromorphine 
• 1403776-94-2 4,5-epoxy-17-methyl-(5α,6α)-morphinan-3,6-diol 3,6-dibenzoate 
• 1403776-86-2 4,5-epoxy-17-methyl-(5α,6α)-morphinan-3,6-diol 3-benzoate 6-acetate 

Relevant articles and documents

Stereoselective reduction method of morphinone compounds

The invention discloses a stereoselective reduction method of morphinone compounds. The stereoselective reduction method comprises the step as follows: the morphinone compounds and tetramethylammonium triacetoxyborohydride are subjected to a reaction in an organic solvent in the presence of acid. A reducing agent, namely, tetramethylammonium triacetoxyborohydride, used in the method is convenient to prepare, low in cost, easy to store and non-corrosive to equipment, besides, reaction yield can basically reach about 99%, and de value can reach 98% or higher.

On the selection of an opioid for local skin analgesia: Structure-skin permeability relationships

Recent studies demonstrated that post-herpetical and inflammatory pain can be locally managed by morphine gels, empirically chosen. Aiming to rationalize the selection of the most suitable opioid for the cutaneous delivery, we studied the in vitro penetration through human epidermis of eight opioids, evidencing the critical modifications of the morphinan core. Log P, log D, solid-state features and solubility were determined. Docking simulations were performed using supramolecular assembly made of ceramide VI. The modifications on position 3 of the morphinan core resulted the most relevant in determining both physicochemical characteristics and diffusion pattern. The 3-methoxy group weakened the cohesiveness of the crystal lattice structure and increased the permeation flux (J). Computational studies emphasized that, while permeation is essentially controlled by molecule apolarity, skin retention depends on a fine balance of polar and apolar molecular features. Moreover, ChemPLP scoring the interactions between the opioids and ceramide, correlated with both the amount retained into the epidermis (Qret) and J. The balance of the skin penetration properties and the affinity potency for μ-receptors evidenced hydromorphone as the most suitable compound for the induction of local analgesia.

IMPROVED PROCESS FOR THE PREPARATION OF 6-ALPHA-HYDROXY-N-ALKYLATED OPIATES

The present invention is directed to the conversion of a 6-keto morphinan to a 6-alpha-hydroxy morphinan in the presence of a ruthenium, rhodium, or iridium asymmetric catalyst and a hydrogen source.